Campbell & CO Investment Adviser LLC Invests $439,000 in Syndax Pharmaceuticals, Inc. $SNDX

Campbell & CO Investment Adviser LLC purchased a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 46,829 shares of the company’s stock, valued at approximately $439,000. Campbell & CO Investment Adviser LLC owned approximately 0.05% of Syndax Pharmaceuticals at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. Quarry LP bought a new position in Syndax Pharmaceuticals in the 1st quarter valued at approximately $25,000. Teacher Retirement System of Texas raised its stake in shares of Syndax Pharmaceuticals by 11.9% in the second quarter. Teacher Retirement System of Texas now owns 23,132 shares of the company’s stock worth $217,000 after purchasing an additional 2,458 shares during the last quarter. DAFNA Capital Management LLC lifted its holdings in shares of Syndax Pharmaceuticals by 0.5% during the first quarter. DAFNA Capital Management LLC now owns 544,502 shares of the company’s stock valued at $6,689,000 after purchasing an additional 2,500 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Syndax Pharmaceuticals by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,842 shares of the company’s stock valued at $705,000 after buying an additional 3,094 shares during the last quarter. Finally, E Fund Management Co. Ltd. increased its holdings in Syndax Pharmaceuticals by 27.2% in the 1st quarter. E Fund Management Co. Ltd. now owns 16,031 shares of the company’s stock worth $197,000 after buying an additional 3,428 shares in the last quarter.

Analyst Ratings Changes

SNDX has been the topic of a number of research reports. JPMorgan Chase & Co. dropped their price target on Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 12th. Stifel Nicolaus assumed coverage on shares of Syndax Pharmaceuticals in a research report on Wednesday, September 10th. They set a “buy” rating and a $44.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Syndax Pharmaceuticals in a research note on Monday, October 27th. Wall Street Zen upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $35.90.

Insider Buying and Selling

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 157,307 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $16.41, for a total value of $2,581,407.87. Following the completion of the sale, the chief executive officer owned 298,661 shares of the company’s stock, valued at approximately $4,901,027.01. This trade represents a 34.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals Stock Down 0.2%

Syndax Pharmaceuticals stock opened at $16.62 on Monday. The business has a fifty day moving average of $15.28 and a two-hundred day moving average of $12.77. Syndax Pharmaceuticals, Inc. has a twelve month low of $8.58 and a twelve month high of $18.00. The company has a quick ratio of 4.55, a current ratio of 4.71 and a debt-to-equity ratio of 2.06. The firm has a market cap of $1.44 billion, a P/E ratio of -4.27 and a beta of 0.73.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.04. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The business had revenue of $45.87 million for the quarter, compared to analysts’ expectations of $49.08 million. During the same period last year, the business earned ($0.98) EPS. The company’s revenue was up 266.4% compared to the same quarter last year. On average, analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).